TOP STORIES
cardiology
Arrhythmia

Rivaroxaban gets approval for use in patients with renal impairment


Rivaroxaban (Xarelto) is now approved in Australia for patients with severe renal impairment down to a creatinine clearance of 15 mL/min. The change brings the DOACs use in Australia into line with other countries including in Europe, the US and Canada. Associate...

Rivaroxaban (Xarelto) is now approved in Australia for patients with severe renal impairment down to a creatinine clearance of 15...

Read more